11 – 20 of 34
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial
(
- Contribution to journal › Article
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
(
- Contribution to journal › Article
- 2012
-
Mark
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
(
- Contribution to journal › Article
-
Mark
Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
(
- Contribution to journal › Article
-
Mark
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
(
- Contribution to journal › Article
- 2011
-
Mark
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
(
- Contribution to journal › Article
- 2010
-
Mark
Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden.
(
- Contribution to journal › Article